HC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00

Keros Therapeutics (NASDAQ:KROS) had its price objective decreased by HC Wainwright from $25.00 to $20.00 in a report published on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other equities research analysts also recently commented on KROS. Wedbush reaffirmed a “neutral” rating and set a $15.00 target price on shares of Keros Therapeutics in a report on Friday, May 30th. Bank of America downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $32.00 to $18.00 in a report on Tuesday, June 10th. Finally, Scotiabank decreased their target price on Keros Therapeutics from $41.00 to $26.00 and set a “sector outperform” rating for the company in a report on Monday, May 12th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Keros Therapeutics has an average rating of “Moderate Buy” and an average price target of $30.00.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS opened at $13.73 on Friday. The company has a market cap of $557.71 million, a PE ratio of 44.29, a P/E/G ratio of 1.80 and a beta of 1.33. The business has a 50-day simple moving average of $14.03 and a two-hundred day simple moving average of $12.80. Keros Therapeutics has a fifty-two week low of $9.12 and a fifty-two week high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.38. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%. The company’s quarterly revenue was up 49002.7% on a year-over-year basis. During the same quarter last year, the company earned ($1.25) earnings per share. On average, sell-side analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of KROS. ADAR1 Capital Management LLC raised its position in Keros Therapeutics by 6,294.5% during the first quarter. ADAR1 Capital Management LLC now owns 1,486,461 shares of the company’s stock valued at $15,147,000 after acquiring an additional 1,463,215 shares in the last quarter. Braidwell LP raised its position in Keros Therapeutics by 167.9% during the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company’s stock valued at $29,989,000 after acquiring an additional 1,187,199 shares in the last quarter. Federated Hermes Inc. increased its position in shares of Keros Therapeutics by 882.3% in the first quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company’s stock valued at $12,474,000 after buying an additional 1,099,519 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Keros Therapeutics by 31.1% in the first quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company’s stock valued at $26,151,000 after buying an additional 609,212 shares in the last quarter. Finally, Lynx1 Capital Management LP purchased a new stake in shares of Keros Therapeutics in the fourth quarter valued at approximately $8,612,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.